The Effect of Dosage of Caffeine on Intraocular Pressure
NCT ID: NCT01793311
Last Updated: 2013-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2013-02-28
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Eligible subjects will be randomized into three groups:
1. group 1: intake of decaffeinated coffee
2. group 2: intake of coffee with lower caffeine dose
3. group 3: intake of coffee with higher caffeine dose
Intraocular pressure will be measured at 0, 30, 60 and 90 minutes after coffee intake.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Caffeinated Coffee on Intraocular Pressure
NCT01364207
Caffeine Consumption in Glaucoma Patients and Healthy Subjects
NCT03675412
Evaluation of the Water Drinking Test Response in Supine and Sitting Position Using the Continuous Measurement Device Sensimed Triggerfish Intraocular Pressure in Healthy Subjects
NCT02843971
IOP Lowering Effects of Topical Anesthetics Used Frequently in the Ophthalmology Clinic
NCT01254149
Relationship Between Central Corneal Thickness and Intraocular Pressure Measures Instruments.
NCT00347191
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
all three groups' intraocular pressure will be measured with the Goldmann applanation tonometer at 4 timepoints:
1. 0 minutes (baseline)
2. 30 minutes after intake
3. 60 minutes after intake
4. 90 minutes after intake
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group1: Decaffeinated coffee
contains 0.5-2 mg of caffeine
decaffeinated coffee
contains caffeine 0.5-2 mg
Group2: regular dose coffee
contains 91.8 mg of caffeine
regular dose coffee
contains 91.8 mg of caffeine
Group3: high dose coffee
contains 144 mg of caffeine
high dose coffee
contains 144 mg of caffeine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
decaffeinated coffee
contains caffeine 0.5-2 mg
regular dose coffee
contains 91.8 mg of caffeine
high dose coffee
contains 144 mg of caffeine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* normal central corneal thickness
* normal baseline intraocular pressure
Exclusion Criteria
* baseline intraocular pressure over 21 mmHg
* central corneal thickness less than 520 microns or more than 540 microns
20 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chiang Mai University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Damrong Wiwatwongwana
M.D.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Damrong Wiwatwongwana, M.D.
Role: PRINCIPAL_INVESTIGATOR
Chiang Mai University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chiang Mai University Hospital
Muang, Chiang Mai, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OPT-11-03-03A-12-X
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.